$ARQT News

Arcutis Biotherapeutics (NASDAQ:ARQT): A Decent Value Stock With Growth Momentum

Arcutis Biotherapeutics’ Subsidiary Arcutis Canada Secures Health Canada Approval For Roflumilast Cream In Pediatric Atopic Dermatitis Patients

Arcutis Biotherapeutics (NASDAQ:ARQT) Pairs High Growth Momentum with a Breakout Setup

Arcutis Biotherapeutics (NASDAQ:ARQT) Matches Navellier's Growth Playbook With Accelerating Fundamentals

Arcutis Biotherapeutics (NASDAQ:ARQT) Pairs Strong Growth with a Timely Technical Setup

Morgan Stanley Maintains Overweight on Arcutis Biotherapeutics, Raises Price Target to $38

Arcutis Biotherapeutics, Inc. 2026 Q2 - Results - Earnings Call Presentation

Arcutis President and CEO Todd Watanabe Sells 4,375 Shares for $114,275 as Q2 Results Demonstrate Profitability

Arcutis Biotherapeutics, Inc. Q2 2026 Earnings Call Summary

Guggenheim Maintains Buy on Arcutis Biotherapeutics, Raises Price Target to $38

Needham Maintains Buy on Arcutis Biotherapeutics, Raises Price Target to $40

Arcutis Biotherapeutics Inc (ARQT) (Q2 2026) Earnings Call Highlights: Revenue Surges 59% and ...

Arcutis Biotherapeutics Q2 Earnings Call Highlights

Arcutis Biotherapeutics, Inc. (ARQT) Q2 2026 Earnings Call Transcript

Arcutis Biotherapeutics, Inc. (ARQT) Q2 Earnings and Revenues Surpass Estimates

Arcutis Biotherapeutics (NASDAQ:ARQT) Jumps on Q2 Beat and Raised Guidance

Arcutis Announces Second Quarter 2026 Financial Results and Provides Business Update

Arcutis Biotherapeutics Q2 EPS $0.11 Beats $0.03 Estimate, Sales $129.861M Beat $118.852M Estimate

Arcutis Biotherapeutics (ARQT) Stock Trades At A Discount To Sales But Fair Value Looks Tight

Arcutis Biotherapeutics (ARQT) Heads Into Earnings With Its ZORYVE Story Still Shaping Valuation